Wells Fargo & Company MN grew its holdings in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 27.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 208,816 shares of the biotechnology company’s stock after acquiring an additional 44,658 shares during the period. Wells Fargo & Company MN owned about 0.30% of Progenics Pharmaceuticals worth $1,537,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also bought and sold shares of the company. Piedmont Investment Advisors LLC acquired a new position in shares of Progenics Pharmaceuticals in the second quarter worth $103,000. Numeric Investors LLC acquired a new position in shares of Progenics Pharmaceuticals in the second quarter worth $2,877,000. Los Angeles Capital Management & Equity Research Inc. grew its stake in shares of Progenics Pharmaceuticals by 457.2% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 88,980 shares of the biotechnology company’s stock worth $655,000 after acquiring an additional 73,010 shares in the last quarter. Hikari Power Ltd acquired a new position in shares of Progenics Pharmaceuticals in the third quarter worth $1,472,000. Finally, New York State Common Retirement Fund grew its stake in shares of Progenics Pharmaceuticals by 11.0% in the second quarter. New York State Common Retirement Fund now owns 239,525 shares of the biotechnology company’s stock worth $1,626,000 after acquiring an additional 23,723 shares in the last quarter. Institutional investors and hedge funds own 84.55% of the company’s stock.
Several research firms have commented on PGNX. ValuEngine downgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Cantor Fitzgerald restated a “buy” rating and issued a $15.00 price target on shares of Progenics Pharmaceuticals in a research note on Wednesday, September 27th. Zacks Investment Research downgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Finally, BidaskClub upgraded shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $12.35.
Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. The business had revenue of $2.70 million during the quarter, compared to analysts’ expectations of $3.58 million. Progenics Pharmaceuticals had a negative net margin of 445.81% and a negative return on equity of 67.61%. The company’s revenue for the quarter was down 95.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.52 EPS. research analysts expect that Progenics Pharmaceuticals, Inc. will post -0.92 earnings per share for the current fiscal year.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.